Mountain Valley MD: Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested With Ivectosol™ [Ivermectin]

Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested With Ivectosol™

Mountain Valley MD (Preprint) (In Vitro)

Mountain Valley MD, Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested.., (Preprint) (In Vitro)

May 2021 Source PDF

Twitter
Facebook

All Studies Meta

In Vitro and mouse study with human ACE2 cells, using solubilized ivermectin with Ivectosol™, showing antiviral effect with B.1.1.7, B.1.351, and P.1 variants of SARS-CoV-2.

The ability to inject ivermectin potentially reduces the onset of action from ~6 hours to ~15 minutes, with much lower variability.

15 In Vitro studies support the efficacy of ivermectin [Boschi, Caly, Croci, De Forni, Delandre, Jeffreys, Jitobaom, Jitobaom (B), Li, Liu, Mody, Mountain Valley MD, Segatori, Surnar, Yesilbag].

Important missing comments or errors? Let us know.

1. Boschi et al., bioRxiv, doi:10.1101/2022.11.24.517882, SARS-CoV-2 Spike Protein Induces Hemagglutination: Implications for COVID-19 Morbidities and Therapeutics and for Vaccine Adverse Effects, https://www.biorxiv.org/content/10.1101/2022.11.24.517882.

2. Caly et al., Antiviral Research, doi:10.1016/j.antiviral.2020.104787, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, https://www.sciencedirect.com/science/article/pii/S0166354220302011.

3. Croci et al., International Journal of Biomaterials, doi:10.1155/2016/8043983, Liposomal Systems as Nanocarriers for the Antiviral Agent Ivermectin, http://www.hindawi.com/journals/ijbm/2016/8043983/.

4. De Forni et al., PLoS ONE, doi:10.1371/journal.pone.0276751, Synergistic drug combinations designed to fully suppress SARS-CoV-2 in the lung of COVID-19 patients, https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0276751.

5. Delandre et al., Pharmaceuticals, doi:10.3390/ph15040445, Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, https://www.mdpi.com/1424-8247/15/4/445.

6. Jeffreys et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2022.106542 (preprint 12/24/2020), Remdesivir-ivermectin combination displays synergistic interaction with improved in vitro activity against SARS-CoV-2, https://www.sciencedirect.com/science/article/pii/S0924857922000309.

7. Jitobaom et al., BMC Pharmacology and Toxicology, doi:10.1186/s40360-022-00580-8 (preprint 11/30/2021), Synergistic anti-SARS-CoV-2 activity of repurposed anti-parasitic drug combinations, https://bmcpharmacoltoxicol.biomed..rticles/10.1186/s40360-022-00580-8.

8. Jitobaom (B) et al., Research Square, doi:10.21203/rs.3.rs-941811/v1, Favipiravir and Ivermectin Showed in Vitro Synergistic Antiviral Activity against SARS-CoV-2, https://www.researchsquare.com/article/rs-941811/v1.

9. Li et al., J. Cellular Physiology, doi:10.1002/jcp.30055, Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment, https://onlinelibrary.wiley.com/doi/10.1002/jcp.30055.

10. Liu et al., bioRxiv, doi:10.1101/2022.01.20.477147, SARS-CoV-2 Viral Genes Compromise Survival and Functions of Human Pluripotent Stem Cell-derived Cardiomyocytes via Reducing Cellular ATP Level, https://www.biorxiv.org/content/10.1101/2022.01.20.477147.

11. Mody et al., Communications Biology, doi:10.1038/s42003-020-01577-x, Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, https://www.nature.com/articles/s42003-020-01577-x.

12. Mountain Valley MD, Mountain Valley MD Receives Successful Results From BSL-4 COVID-19 Clearance Trial on Three Variants Tested With Ivectosol™, https://www.globenewswire.com/en/n..ariants-Tested-With-Ivectosol.html.

13. Segatori et al., Viruses, doi:10.3390/v13102084, Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients, https://www.mdpi.com/1999-4915/13/10/2084.

14. Surnar et al., ACS Pharmacol. Transl. Sci., doi:10.1021/acsptsci.0c00179, Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19, https://pubs.acs.org/doi/abs/10.1021/acsptsci.0c00179.

15. Yesilbag et al., Virus Research, doi:10.1016/j.virusres.2021.198384, Ivermectin also inhibits the replication of bovine respiratory viruses (BRSV, BPIV-3, BoHV-1, BCoV and BVDV) in vitro, https://www.sciencedirect.com/science/article/pii/S0168170221000915.

Mountain Valley MD et al., 18 May 2021, preprint, 1 author.

In Vitro studies are an important part of preclinical research, however results may be very different in vivo.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Ivermectin All

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit